Antipsychotics - Articles - Page 11

Saphris Approved for Pediatric Bipolar Disorder—What Do the Data Show?

April 1, 2015

In March 2015, the US Food and Drug Administration (FDA) approved Actavis’ asenapine (Saphris) for the acute treatment of manic or mixed episodes associated with bipolar disorder in kids between 10 and 17 years.

Latuda: An Evaluation of Its Usefulness

February 1, 2015

Daniel Carlat, MD

Daniel Carlat, MD Editor-in-Chief, Publisher, The Carlat Report. Dr. Carlat has disclosed that he has no relevant relationships or financial interests in any commercial company pertaining to this educational activity.

With nine other atypical antipsychotics already on the market (some of which are available as generics), did we really need another one? Given the pesky side effects of antipsychotics, maybe we did. Let’s take a look at what we know so far about Latuda (lurasidone) in an effort to figure out how to incorporate it into our clinical toolbox. Latuda was first approved by the US Food and Drug Administration (FDA) for use in schizophrenia in late 2010.

The New Emphasis on Community Functioning in Schizophrenia

February 1, 2015

Dost Ongur, PhD, MD and Daniel Carlat, MD

Dost Ongur, PhD, MD Chief, Psychotic Disorders Division, McLean Hospital, Belmont, MA Associate Professor of Psychiatry, Harvard Medical School Dr. Ongur has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity. Daniel Carlat, MD Editor-in-Chief, Publisher, The Carlat Report. Dr. Carlat has disclosed that he has no relevant relationships or financial interests in any commercial company pertaining to this educational activity.

Learn about the new emphasis on community functioning for patients with schizophrenia, in an interview with Dost Ongur, MD, PhD, chief of the psychotic disorders division at McLean Hospital and an associate professor of psychiatry at Harvard Medical School.

FDA Issues Alert for Geodon

February 1, 2015

In December 2014, the US Food and Drug Administration (FDA) issued a safety announcement warning that the antipsychotic drug ziprasidone (Geodon) has been associated with a rare but potentially fatal skin reaction.

The New FDA-Approved EEG Test for ADHD: Should You Order It?

December 1, 2014

Daniel Carlat, MD

Over the decades, finding a truly useful objective diagnostic test in psychiatry has proven both elusive and frustrating.

Table - Antipsychotic Medications Used for Children

December 1, 2014

Table: Antipsychotic Medications Used for Children (Click here to view as a full-size PDF.) ...

Table - Possible Side Effects of Antipsychotic Medications

December 1, 2014

Table: Possible Side Effects of Antipsychotic Medications (Click here to view as a full-size PDF.) ...

Using Antipsychotics Judiciously in Children

December 1, 2014

Glen Elliott, MD, PhD

Glen R. Elliott, MD, PhD
Chief Psychiatrist and Medical Director Children’s Health Council, Palo Alto, CA. Clinical Professor (Affiliated), Stanford University School of Medicine, Division of Child and Adolescent Psychiatry.
Dr. Elliott has disclosed that he has no relevant relationshipt or financial interests in any commercial company pertaining to this educational activity.

Read about the appropriate use of antipsychotics to treat disorders in children and adolescents, in an interview with psychiatrist Glen R. Elliott, MD, PhD.

Dealing With Side Effects of SSRIs

May 1, 2014

Pavan Madan, MD

Selective serotonin reuptake inhibitors (SSRIs) are widely used as the first-line treatment for depression and anxiety in children and adolescents, but they are associated with significant adverse effects (AEs). Studies have shown that up to 50% of kids experience side effects from SSRIs, depending on the sample size and the type of study.

Metabolic and Extrapyramidal Effects of Antipsychotics

May 1, 2014

Tamara Pringsheim, MD

Tamara Pringsheim, MD
Assistant Professor, Department of Clinical Neurosciences, Psychiatry, Pediatrics and Community Health Sciences University of Calgary.
Dr. Pringsheim has disclosed that she has been a paid consultant to Teva Neuroscience, Allergan, and Shire Canada. The editors have reviewed this interview and found no evidence of bias in this educational activity.

Pharmacoepidemiologist Tamara Pringsheim, MD, describes strategies for dealing with metabolic, extrapyramidal, and hormonal side effects of antipsychotics.